VIDEO: IMbrave050 study a ‘huge breakthrough’ in hepatocellular carcinoma
In this video, James Cleary, MD, PhD, a medical oncologist at Dana-Farber Cancer Institute, discussed results from the phase 3 IMbrave050 trial, presented at American Association for Cancer Research Annual Meeting.
Cleary highlighted the study, which found increased recurrence-free survival of patients with hepatocellular carcinoma treated with adjuvant therapy with atezolizumab (Tecentriq, Genentech) and bevacizumab (Avastin, Genentech) — although not without its drawbacks.
“The one fly in the ointment is that there were more treatment-related deaths on the atezolizumab-bevacizumab arm,” Cleary said. “But fingers crossed, because this could really be a great gain for our patients.”
Collapse
Read more about